"Today's decision marks an important milestone for Calmark. We can now ascertain that we can satisfy our technical requirements on measurement accuracy. The results of analysis fall within the expected range when compared to the reference laboratory at Karolinska University Hospital. We are confident to bring the first biomarker, bilirubin, into the final phase of the project," says Anna Söderlund, CEO of Calmark. "Since the reader obtains its CE marking together with each respective biomarker, the initial project is also the most extensive - so I am very happy that we are on our way to achieve this."